進行性固形腫瘍患者の治療におけるエルロチニブ塩酸塩とイリノテカン塩酸塩
進行性固形腫瘍患者における OSI-774 および CPT-11 の第 I 相試験
Phase I trial to study the effectiveness of combining erlotinib hydrochloride with irinotecan hydrochloride in treating patients who have advanced solid tumors. Erlotinib hydrochloride may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining erlotinib hydrochloride and chemotherapy may kill more tumor cells.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
OBJECTIVES:
I. Determine the maximum tolerated dose (MTD) of erlotinib (erlotinib hydrochloride) and irinotecan (irinotecan hydrochloride), in relation to presence or absence of UGT1A1*28 polymorphism, in patients with advanced solid tumors that overexpress epidermal growth factor receptor.
II. Determine the dose-limiting toxicity of these regimens in these patients. III. Determine whether erlotinib alters the disposition of irinotecan using a previously described limited sampling model.
IV. Determine factors that influence the disposition of these drugs, including genetic variation in UGT1A1 and BCRP, in patients treated with these regimens.
V. Determine factors that influence the disposition of these drugs, in terms of tumor BCRP-expression, in tumor samples from patients treated with these drugs at the MTD.
VI. Evaluate the effect of this regimen on epidermal growth factor receptor phosphorylation in these patients.
VII. Assess, preliminarily, any antitumor activity in patients treated with these regimens.
VIII. Correlate, preliminarily, EGFR phosphorylation and/or BCRP -expression with response in tumor samples from these patients.
OUTLINE: This is a dose-escalation study. Patients are stratified according to UGTA1A genotype (all patients regardless of genotype [closed to accrual as of 9/15/04] vs UGT1A1 6/6 genotype vs UGTA1A 6/7 or 7/7 genotype).
Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride intravenously (IV) over 90 minutes on day 1 and oral erlotinib once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients per stratum receive escalating doses of erlotinib hydrochloride and irinotecan hydrochloride until the MTD is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Additional patients are treated at the MTD.
Patients are followed for 3 months.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic in Rochester
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Histologically confirmed malignancy that overexpresses epidermal growth factor receptor (EGFR)
- Unresectable disease for which there is no known standard therapy that ispotentially curative or definitely capable of extending life expectancy
- UGT1A1 genotype 6/6, 6/7, or 7/7
- Willing to provide biologic specimens
- Lesions amenable for 2 biopsies from the same tumor site (only patients receiving MTD in groups 2 and 3)
- No known brain metastases
- Performance status - ECOG 0-2
- At least 12 weeks
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9.0 g/dL
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- AST ≤ 2.5 times ULN (5 times ULN if liver metastases present)
- Creatinine no greater than 1.5 times ULN
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No New York Heart Association class III or IV heart disease
- No gastrointestinal tract disease resulting in an inability to take oral or nasogastric medication
- No requirement for IV alimentation
- No active peptic ulcer disease
- No abnormalities of the cornea (e.g., dry eye syndrome or Sjögren's syndrome)
- No congenital abnormality (e.g., Fuch's dystrophy)
- No abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
- No abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)
- No other uncontrolled concurrent illness
- No ongoing or active infection
- No significant traumatic injury within the past 21 days
- No seizure disorder
- No psychiatric illness or social situation that would preclude study compliance
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No concurrent grapefruit or grapefruit juice
- No smoking during study
- More than 4 weeks since prior immunotherapy or biologic therapy
- No concurrent immunotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No other concurrent chemotherapy
- Not specified
- More than 4 weeks since prior radiotherapy
- No prior radiotherapy to more than 25% of bone marrow
- No concurrent radiotherapy
- More than 3 weeks since prior major surgery
- No prior surgical procedures affecting absorption
- No prior EGFR-targeting therapy (e.g., gefitinib or EKB-569)
- No other concurrent investigational therapy
- No concurrent enzyme-inducing anticonvulsants (e.g., phenytoin, phenobarbital, carbamazepine, or valproic acid)
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent enrollment on another study involving pharmacological agents for symptom control or therapeutic intent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Treatment (enzyme inhibitor, chemotherapy)
Patients receive oral erlotinib hydrochloride daily on days -6 to -1. Patients then receive irinotecan hydrochloride IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given orally
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
MTDでのEGFRリン酸化に対するエルロチニブの効果
時間枠:コース1中は毎週
|
コース1中は毎週
|
|
|
MTDで治療された患者における腫瘍BCRP発現
時間枠:コース1中は毎週
|
コース1中は毎週
|
|
|
MTD of erlotinib hydrochloride and irinotecan hydrochloride in patients with advanced solid tumors that overexpress epidermal growth factor receptor
時間枠:At least 4 weeks
|
Defined as the highest safely tolerated dose where at most one patient experiences DLT with the next higher dose having at least 2 patients who experience DLT. Three patients will be entered at a given dose level and observed for at least 4 weeks to assess toxicity. MTD will be determined independently for each cohort. |
At least 4 weeks
|
|
Dose limiting toxicity of the combination in all cohorts
時間枠:At least 4 weeks
|
Defined as an adverse event attributed (definitely, probably, or possibly) to the study treatment. Graded using the National Cancer Institute Common Toxicity Criteria (CTC) version 2.0. Defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE) versioun 4.0. |
At least 4 weeks
|
|
Effect of erlotinib hydrochloride on the disposition of irinotecan hydrochloride
時間枠:Weekly during course 1
|
Analysis performed using high performance liquid chromatography assays. Serial blood samples will be obtained during Cycle 1 only to determine the pharmacokinetics of irinotecan hydrochloride and erlotinib hydrochloride. |
Weekly during course 1
|
|
Genetic variation in UGT1A1 and BCRP
時間枠:Weekly during course 1
|
Detected using allele-specific restriction fragment length polymorphism (RFLP) assays and GeneScan assays. The overall incidence of UTG1A1 polymorphism will be estimated and summarized. |
Weekly during course 1
|
|
Evidence of anti tumor activity
時間枠:Every 3 weeks
|
Evaluated using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. |
Every 3 weeks
|
|
Correlation of EGFR phosphorylation and/or BCRP expression with response to this combination
時間枠:Every 3 weeks
|
Evaluated using modified RECIST criteria. |
Every 3 weeks
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Henry C Pitot、Mayo Clinic
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (推定)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- NCI-2009-00015
- P30CA015083 (米国 NIH グラント/契約)
- U01CA069912 (米国 NIH グラント/契約)
- NCI-2009-00015 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- CDR0000256910
- 594-02 01
- NCI-5351
- MAYO-MC0112
- MC0112 (その他の識別子:Mayo Clinic in Rochester)
- 5351 (その他の識別子:CTEP)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。